Breast Cancer Imaging Using the Near-Infrared Fluorescent Agent, CLR1502
Positive margins after breast conservation surgery represent a significant problem in the treatment of breast cancer. The near-infrared fluorescence agent CLR1502 (Cellectar Biosciences, Madison, WI) was studied in a preclinical breast cancer model to determine imaging properties and ability to dete...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2015-01-01
|
| Series: | Molecular Imaging |
| Online Access: | https://doi.org/10.2310/7290.2014.00040 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841564563467665408 |
|---|---|
| author | Melissa L. Korb Jason M. Warram Joseph Grudzinski Jamey Weichert Justin Jeffery Eben L. Rosenthal |
| author_facet | Melissa L. Korb Jason M. Warram Joseph Grudzinski Jamey Weichert Justin Jeffery Eben L. Rosenthal |
| author_sort | Melissa L. Korb |
| collection | DOAJ |
| description | Positive margins after breast conservation surgery represent a significant problem in the treatment of breast cancer. The near-infrared fluorescence agent CLR1502 (Cellectar Biosciences, Madison, WI) was studied in a preclinical breast cancer model to determine imaging properties and ability to detect small islands of malignancy. Nude mice bearing human breast cancer flank xenografts were given a systemic injection of CLR1502, and imaging was performed using LUNA (Novadaq Technologies Inc., Richmond, BC) and Pearl Impulse (LI-COR Biosciences, Lincoln, NE) devices. Normal tissues were examined for fluorescence signal, and conventional and fluorescence histology was performed using the Odyssey scanner. Peak tumor to background ratio occurred 2 days after injection with CLR1502. The smallest amount of tumor that was imaged and detected using these devices was 1.9 mg, equivalent to 1.9 × 10 6 cells. The highest fluorescence signal was seen in tumor and normal lymph node tissue, and the lowest fluorescence signal was seen in muscle and plasma. Human breast cancer tumors can be imaged in vivo with multiple optical imaging platforms using CLR1502. This pilot study supports further investigations of this fluorescent agent for improving surgical resection of malignancies, with the goal of eventual clinical translation. |
| format | Article |
| id | doaj-art-a21523e6c27d4633a35d737d6ecee906 |
| institution | Kabale University |
| issn | 1536-0121 |
| language | English |
| publishDate | 2015-01-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Molecular Imaging |
| spelling | doaj-art-a21523e6c27d4633a35d737d6ecee9062025-01-02T22:37:22ZengSAGE PublishingMolecular Imaging1536-01212015-01-011410.2310/7290.2014.0004010.2310_7290.2014.00040Breast Cancer Imaging Using the Near-Infrared Fluorescent Agent, CLR1502Melissa L. KorbJason M. WarramJoseph GrudzinskiJamey WeichertJustin JefferyEben L. RosenthalPositive margins after breast conservation surgery represent a significant problem in the treatment of breast cancer. The near-infrared fluorescence agent CLR1502 (Cellectar Biosciences, Madison, WI) was studied in a preclinical breast cancer model to determine imaging properties and ability to detect small islands of malignancy. Nude mice bearing human breast cancer flank xenografts were given a systemic injection of CLR1502, and imaging was performed using LUNA (Novadaq Technologies Inc., Richmond, BC) and Pearl Impulse (LI-COR Biosciences, Lincoln, NE) devices. Normal tissues were examined for fluorescence signal, and conventional and fluorescence histology was performed using the Odyssey scanner. Peak tumor to background ratio occurred 2 days after injection with CLR1502. The smallest amount of tumor that was imaged and detected using these devices was 1.9 mg, equivalent to 1.9 × 10 6 cells. The highest fluorescence signal was seen in tumor and normal lymph node tissue, and the lowest fluorescence signal was seen in muscle and plasma. Human breast cancer tumors can be imaged in vivo with multiple optical imaging platforms using CLR1502. This pilot study supports further investigations of this fluorescent agent for improving surgical resection of malignancies, with the goal of eventual clinical translation.https://doi.org/10.2310/7290.2014.00040 |
| spellingShingle | Melissa L. Korb Jason M. Warram Joseph Grudzinski Jamey Weichert Justin Jeffery Eben L. Rosenthal Breast Cancer Imaging Using the Near-Infrared Fluorescent Agent, CLR1502 Molecular Imaging |
| title | Breast Cancer Imaging Using the Near-Infrared Fluorescent Agent, CLR1502 |
| title_full | Breast Cancer Imaging Using the Near-Infrared Fluorescent Agent, CLR1502 |
| title_fullStr | Breast Cancer Imaging Using the Near-Infrared Fluorescent Agent, CLR1502 |
| title_full_unstemmed | Breast Cancer Imaging Using the Near-Infrared Fluorescent Agent, CLR1502 |
| title_short | Breast Cancer Imaging Using the Near-Infrared Fluorescent Agent, CLR1502 |
| title_sort | breast cancer imaging using the near infrared fluorescent agent clr1502 |
| url | https://doi.org/10.2310/7290.2014.00040 |
| work_keys_str_mv | AT melissalkorb breastcancerimagingusingthenearinfraredfluorescentagentclr1502 AT jasonmwarram breastcancerimagingusingthenearinfraredfluorescentagentclr1502 AT josephgrudzinski breastcancerimagingusingthenearinfraredfluorescentagentclr1502 AT jameyweichert breastcancerimagingusingthenearinfraredfluorescentagentclr1502 AT justinjeffery breastcancerimagingusingthenearinfraredfluorescentagentclr1502 AT ebenlrosenthal breastcancerimagingusingthenearinfraredfluorescentagentclr1502 |